Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
about
Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasionCIViC databaseEpidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Aurora kinases in head and neck cancerManagement of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentTargeting secondary immune responses to cetuximab: CD137 and the outside story.Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significanceEGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximabXenograft assessment of predictive biomarkers for standard head and neck cancer therapiesEpidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck.Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialComprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.Targeted therapy in cancer.Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Molecular profiling of head and neck squamous cell carcinoma.Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerEpidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas.The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Prognostic and predictive value of EGFR in head and neck squamous cell carcinomaSystemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomasComparative molecular profiling of HPV-induced squamous cell carcinomas.EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies.Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma.Emerging functions of the EGFR in cancer.Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: final results from a single institution.Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts.
P2860
Q26825164-5659C6AC-BBF2-453D-9DE3-58B488D28FFCQ27612411-0A05C159-33BB-4BD8-B848-1B58E6A11221Q27853131-F893670C-7202-4EFA-9F21-CFB535906BB6Q28654389-20E35FE0-6A0C-439B-AFDB-804622765B85Q30252081-7B6BFC9A-70A7-4872-B05A-711DE094D8B5Q33601653-93BFBA23-09E3-405C-8738-B8F885CEF8F5Q33607965-820B36B0-C353-4D58-B615-F4C91E718597Q33872496-C84F415C-EC4A-491E-B452-9E9BFCB89D60Q33924908-22FA284E-6C1E-4D37-806D-D8B1753C4C0DQ34020601-6C1ED6B2-6F5B-4B30-81EE-A69D43624943Q35042323-C00CBA55-98AC-448D-BA69-820D2D091E9BQ35602135-B86A8AD3-FF66-4F85-B406-DA1E0D789CC1Q35975142-0A26EEC4-730A-43CF-876F-C5CB0C25DC76Q36117785-104DD564-D19E-4811-AC44-4105380F7AE8Q36194219-8EB58A14-FE8A-4A2D-BB2E-1899BE9F55D4Q36685452-75778FCA-D7D4-4BC2-981F-4BDECD4CF481Q36750569-3FC87EA8-69BD-43A5-B0B4-F4DFA31041F2Q37204270-297B73CA-70D3-4867-91C8-468282DA1934Q37321131-9A3CEE75-F9D8-4F65-B328-9E37AC26F5E7Q37337359-A6A88C54-870F-47E8-9269-B0040C08F86EQ37711811-60BE38A1-C5FD-41BE-B006-9B84DE872950Q37723692-19879282-1E48-4BBF-B6CA-F43DE317862AQ38162129-C28F4F83-9BD9-45D3-AF65-A31F014BE800Q38219290-9BC5DC5C-B135-40AF-88A8-0EF45E2A0F4AQ38221292-F7614D3C-5105-4919-A387-46FF2525E598Q38388575-D3B90ED6-5171-4321-AE0D-0ACBB01B9140Q38773904-D25D2337-BD11-4396-9B78-E603EEA99E9BQ38841850-F4DA0E86-32C5-485B-B6CE-B59285D0CB63Q38892486-FDACDEBE-BBAC-4094-9A21-B68785CEADEAQ38935842-40601111-117D-4E9A-BF58-E34102CEB343Q38971558-668E7113-2525-41F1-A57F-CE5B8C6DCA9EQ39111192-41F6091A-88E8-4942-9025-FD1C8CFF844AQ40193932-4C0B1F96-45A4-4878-AD2E-2BF42E2BD43AQ41219232-E9542E99-9758-40C5-A6F7-165E550FA13BQ41613206-14790082-D820-4E7D-922F-FAD28772613DQ46383461-EEC72701-85A5-439D-92ED-03040B233CFAQ47124344-1DC0A9F4-E45C-401D-9970-229A1310DB19Q47165377-49E90CD9-719A-4304-B4AA-4E84D4BB1E6DQ47994407-52FD6E75-506C-40E0-BB08-65C919A3E1D9Q50326083-E7BB88F9-0368-475B-B0BD-973CDDF9DDDE
P2860
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@ast
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@en
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@nl
type
label
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@ast
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@en
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@nl
prefLabel
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@ast
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@en
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@nl
P2093
P921
P3181
P1476
Predictive value of epidermal ...... e EXTREME and CRYSTAL studies.
@en
P2093
Anja von Heydebreck
Fred R Hirsch
Ilhan Celik
Jan B Vermorken
Keith M Kerr
Lisa Licitra
Regina Esser
Robert Pirker
Stephan Störkel
P304
P3181
P356
10.1016/J.EJCA.2012.11.018
P577
2013-04-01T00:00:00Z